A detailed history of Citigroup Inc transactions in Fulgent Genetics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 33,092 shares of FLGT stock, worth $666,141. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,092
Previous 22,856 44.78%
Holding current value
$666,141
Previous $448,000 60.27%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$19.6 - $25.06 $200,625 - $256,514
10,236 Added 44.78%
33,092 $718,000
Q2 2024

Aug 12, 2024

BUY
$19.09 - $22.57 $41,482 - $49,044
2,173 Added 10.51%
22,856 $448,000
Q1 2024

May 10, 2024

BUY
$21.55 - $29.29 $138,049 - $187,631
6,406 Added 44.87%
20,683 $448,000
Q4 2023

Feb 09, 2024

BUY
$23.64 - $30.27 $112,029 - $143,449
4,739 Added 49.69%
14,277 $412,000
Q3 2023

Nov 09, 2023

SELL
$26.74 - $40.81 $171,617 - $261,918
-6,418 Reduced 40.22%
9,538 $255,000
Q2 2023

Aug 10, 2023

BUY
$28.52 - $40.7 $145,537 - $207,692
5,103 Added 47.02%
15,956 $590,000
Q1 2023

May 11, 2023

SELL
$29.39 - $36.27 $142,717 - $176,127
-4,856 Reduced 30.91%
10,853 $338,000
Q4 2022

Feb 09, 2023

BUY
$29.23 - $40.28 $141,677 - $195,237
4,847 Added 44.62%
15,709 $467,000
Q3 2022

Nov 10, 2022

BUY
$37.92 - $63.74 $23,131 - $38,881
610 Added 5.95%
10,862 $414,000
Q2 2022

Aug 10, 2022

SELL
$47.98 - $62.75 $475,001 - $621,225
-9,900 Reduced 49.13%
10,252 $559,000
Q1 2022

May 12, 2022

BUY
$49.85 - $96.11 $34,994 - $67,469
702 Added 3.61%
20,152 $1.26 Million
Q4 2021

Feb 10, 2022

BUY
$77.3 - $105.0 $46,843 - $63,630
606 Added 3.22%
19,450 $1.96 Million
Q3 2021

Nov 10, 2021

BUY
$74.87 - $110.87 $1.41 Million - $2.09 Million
18,844 New
18,844 $1.7 Million

Others Institutions Holding FLGT

About Fulgent Genetics, Inc.


  • Ticker FLGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 30,265,800
  • Market Cap $609M
  • Description
  • Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...
More about FLGT
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.